---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-234936"
form_type: "8-K"
ticker: "CERS"
cik: "0001020214"
company_name: "CERUS CORP"
filed_at: "2021-08-03T23:59:59+00:00"
generated_at: "2026-06-29T23:01:51.883306+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Cerus Q2 revenue $37.8M (+41% YoY); raises FY product revenue guidance to $118-122M

## Summary
- Total revenue $37.8M (+41% YoY); product revenue $31.5M (+46%) led by 128% North America platelet growth.
- FY2021 product revenue guidance raised to $118-122M from $110-114M, representing 28-33% growth over 2020.
- Net loss $15.4M ($0.09/sh) vs $14.9M ($0.09) in Q2 2020; cash and investments $122.8M at quarter end.
- Submitted PMA supplement for 7-day INTERCEPT platelet storage; final CE Mark module for INTERCEPT red cells.
- CMS granted NTAP for INTERCEPT Fibrinogen Complex; initial hospital contracts signed; LifeSouth collaboration.

## SEC filing metadata
- accession: 0001193125-21-234936
- form_type: 8-K
- ticker: CERS
- cik: 0001020214
- company_name: CERUS CORP
- filed_at: 2021-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1020214/000119312521234936/0001193125-21-234936-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1020214/000119312521234936/d199644d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-234936
- JSON: https://secwatch.observer/filing/0001193125-21-234936.json
- Plain text: https://secwatch.observer/filing/0001193125-21-234936.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.